mercredi 7 mars 2018

Onco Actu du 7 mars 2018

1. Biologie

Working Toward Greater Precision in Childhood Cancers [NIH Director's Blog]

2. Etiologie

Half of Britons mistakenly believe stress causes cancer [The Guardian]

3.2 Prévention - Obésité

Food industry told to cut calories to tackle obesity [Cancer Research UK]

4. Dépistage, diagnostic et pronostic

Overdiagnosis: when finding cancer can do more harm than good [Cancer Research UK]

4.1 Dép., diag. & prono. - Prostate

Prostate screening saves no lives and may do more harm than good [The Telegraph]

Why a one-off PSA test for prostate cancer is doing men more harm than good [Cancer Research UK]

One-off PSA screening for prostate cancer does not save lives [Cancer Research UK]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

A Major Milestone in Consumer Health Empowerment [23andMe]

FDA Approves Consumer BRCA Test, And We Take Another Step Into The Brave New World Of Genomics [Dr. Len's Blog]

FDA approves first direct-to-consumer test for breast cancer risk [STAT]

23andMe Will Now Test for BRCA Breast-Cancer Genes [The Atlantic]

FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes [FDA]

4.2 Dép., diag. & prono. - Génome

All Cancer Patients Should Have Access To Genomic Testing [Forbes]

5.10 Traitements - Essais

Drug that targets ‘on switch’ in cancer cells moves one step closer [Institute of Cancer Research]

5.12 Immunothérapies

CRISPR enhances cancer immunotherapy [WUSTL]

5.12.2 Immunothérapies - CAR-T

Roswell Park Approved to Administer CAR T-Cell Therapy, Yescarta, to Lymphoma Patients [Roswell Park]

5.12.6 Immunothérapies - AMM

Bristol-Myers Squibb looks for Opdivo convenience edge with new 4-week dosing [FiercePharma]

Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing [BMS]

FDA approves new dosing for Bristol-Myers Squibb's Opdivo [Reuters]

5.12.7 Immunothérapies - vaccins

Oxford Vacmedix moves cancer vaccines forward with $12.5M from South Korea, China [EndPoints]

5.2.1 Pharma - Partenariats

Novartis expands alliance with Science 37 to advance virtual clinical trials program [Novartis]

5.4 Traitements - Economie

Japan cuts prices on BMS and Ono's Opdivo, Merck's Keytruda: report [FiercePharma]

5.6 ESMO

TAT 2018: Novel App Designed to Facilitate Biomarker-Driven Trials of Targeted Anti-Cancer Agents [ESMO]

6. Lutte contre les cancers

Fund ideas, not pedigree, to find fresh insight [Nature]

6.1 Observation

Hundreds of lung cancer patients may be dying early each year [The Guardian]

6.3 Associations/Fondations

Finding common ground with arthritis could help cancer patients [Cancer Research UK]

6.6 Publications

Does your code stand up to scrutiny? [Nature]

Catching the Wave — The Tide Turns Toward the Subscription Model [The Scholarly Kitchen]

When a journal is delisted, authors pay a price [Retraction Watch]

6.7 DMP, Big Data & applis

Lieven Annemans: We need to reach a common understanding about real world data [BMJ Blogs]

6.9 Controverses

Authors of premier medical textbook didn’t disclose $11 million in industry payments [STAT]